How India's Torrent Is Building Resilience In Brazil
This article was originally published in Scrip
Executive Summary
Torrent Pharmaceuticals reported a strong set of numbers for the third quarter ended December 2015, despite turbulence in markets like Brazil, where it has done some sharp "belt tightening", and remains "bullish" long term.
You may also be interested in...
Torrent On Course For Buy, US Momentum
Torrent Pharmaceuticals Ltd may have opted out of the race for the injectables firm Gland Pharma Ltd, but the Indian company stays interested in a buy to build its "hospital presence".
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet